Cellebrite DI Ltd. $CLBT Holdings Increased by Granahan Investment Management LLC

Granahan Investment Management LLC grew its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,057,018 shares of the company’s stock after purchasing an additional 427,719 shares during the period. Cellebrite DI makes up about 2.4% of Granahan Investment Management LLC’s investment portfolio, making the stock its 8th largest position. Granahan Investment Management LLC’s holdings in Cellebrite DI were worth $55,118,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Cellebrite DI by 16.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after purchasing an additional 24,881 shares during the period. Geode Capital Management LLC raised its stake in shares of Cellebrite DI by 16.2% during the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after purchasing an additional 43,898 shares during the period. Invesco Ltd. raised its stake in shares of Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after purchasing an additional 209,473 shares during the period. First Trust Advisors LP purchased a new stake in shares of Cellebrite DI during the second quarter valued at approximately $341,000. Finally, Marshall Wace LLP purchased a new stake in shares of Cellebrite DI during the second quarter valued at approximately $4,472,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CLBT. DA Davidson started coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC decreased their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Cellebrite DI presently has an average rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Trading Down 1.8%

CLBT stock opened at $12.81 on Wednesday. Cellebrite DI Ltd. has a twelve month low of $11.02 and a twelve month high of $19.98. The company has a market capitalization of $3.20 billion, a P/E ratio of 45.75, a PEG ratio of 1.62 and a beta of 1.17. The firm has a 50 day simple moving average of $13.19 and a 200-day simple moving average of $14.98.

Insider Buying and Selling

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders have sold a total of 13,269 shares of company stock valued at $169,592 over the last three months. Insiders own 5.70% of the company’s stock.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.